​

Spruce Biosciences (SPRB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SPRB Stock Forecast

Spruce Biosciences (SPRB) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $131.33, with a high of $150.00 and a low of $104.00. This represents a 135.61% increase from the last price of $55.74.

- $30 $60 $90 $120 $150 High: $150 Avg: $131.33 Low: $104 Last Closed Price: $55.74

SPRB Stock Rating

Spruce Biosciences stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 4 Hold (36.36%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 4 7 Strong Sell Sell Hold Buy Strong Buy

SPRB Price Target Upside V Benchmarks

TypeNameUpside
StockSpruce Biosciences135.61%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts128
Avg Price Target$104.00$113.50$184.13
Last Closing Price$55.74$55.74$55.74
Upside/Downside86.58%103.62%230.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26-7---7
Aug, 2617---8
Jul, 2616---7
Jun, 2614---5
May, 2614---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 17, 2026Guggenheim$104.00$52.6497.57%86.58%
Jun 16, 2026Debjit ChattopadhyayGuggenheim$123.00$49.91146.44%120.67%
Jun 01, 2026H.C. Wainwright$150.00$51.27192.57%169.11%
Apr 27, 2026Albert LoweCraig-Hallum$140.00$55.63151.66%151.17%
Dec 23, 2025Oppenheimer$283.00$82.82241.70%407.71%
Nov 11, 2025JMP Securities$259.00$115.61124.03%364.66%
Oct 28, 2025JMP Securities$254.00$123.02106.47%355.69%
Oct 21, 2025Leerink Partners$160.00$134.0019.40%187.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 26, 2026H.C. WainwrightBuyBuyhold
Aug 17, 2026GuggenheimBuyBuyhold
Aug 13, 2026Goldman SachsOverweightupgrade
Jul 13, 2026B. RileyBuyinitialise
Jun 16, 2026GuggenheimBuyinitialise
May 27, 2026OppenheimerOutperformOutperformhold
Apr 27, 2026Craig-HallumBuyinitialise
Feb 19, 2026H.C. WainwrightBuyBuyhold
Dec 23, 2025OppenheimerOutperformOutperforminitialise
Nov 11, 2025CitigroupOutperformOutperformhold

Financial Forecast

EPS Forecast

$-100 $-80 $-60 $-40 $-20 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-93.00$-96.75$-50.83---
Avg Forecast$-1.40$-0.93$-0.57$-0.62$-0.93$-1.01
High Forecast$-1.30$-0.84$-0.41$-0.15$-0.33$-0.35
Low Forecast$-1.50$-1.07$-0.68$-1.09$-1.53$-1.66
Surprise %6542.86%10303.23%8817.54%---

Revenue Forecast

$0 $6M $12M $18M $24M $30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.09M$4.91M----
Avg Forecast$8.53M$5.09M$900.00K$8.25M$10.75M$19.50M
High Forecast$9.97M$5.60M$1.35M$12.38M$16.13M$29.25M
Low Forecast$7.40M$4.51M$450.00K$4.13M$5.38M$9.75M
Surprise %18.29%-3.58%----

Net Income Forecast

$-65M $-53M $-41M $-29M $-17M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-47.92M$-53.04M----
Avg Forecast$-53.79M$-39.43M$-25.61M$-36.13M$-35.81M$-38.70M
High Forecast$-49.97M$-32.37M$-15.75M$-5.65M$-12.54M$-13.55M
Low Forecast$-57.60M$-41.36M$-26.34M$-41.84M$-59.09M$-63.86M
Surprise %-10.91%34.52%----

SPRB Forecast FAQ

Is Spruce Biosciences stock a buy?

Spruce Biosciences stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spruce Biosciences is a favorable investment for most analysts.

What is Spruce Biosciences's price target?

Spruce Biosciences's price target, set by 11 Wall Street analysts, averages $131.33 over the next 12 months. The price target range spans from $104 at the low end to $150 at the high end, suggesting a potential 135.61% change from the previous closing price of $55.74.

How does Spruce Biosciences stock forecast compare to its benchmarks?

Spruce Biosciences's stock forecast shows a 135.61% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Spruce Biosciences over the past three months?

  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Spruce Biosciences’s EPS forecast?

Spruce Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.62, marking a -98.78% decrease from the reported $-50.83 in 2025. Estimates for the following years are $-0.93 in 2027, and $-1.01 in 2028.

What is Spruce Biosciences’s revenue forecast?

Spruce Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $8.25M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $10.75M, and $19.5M for 2028.

What is Spruce Biosciences’s net income forecast?

Spruce Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-36.125M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-35.815M in 2027, and $-38.703M in 2028.